Korean Drug Developers Turn to Partnering at Bio USA 2026

A wide slate of South Korean pharmaceutical and biotech companies spent four intensive days at Bio USA 2026 focused less on ceremony than on deal-making, packing the schedule with partnering meetings, results presentations, and networking. The delegation spanned early-stage platform developers, contract manufacturers, and established drugmakers, reflecting how central out-licensing and cross-border collaboration have become to Korea’s drug industry.

Who Made the Trip

The Korean contingent brought business-development leaders to the front of the room rather than leaving conference duty to junior staff. Among those named as attending were G2GBIO chief executive Lee Hee-yong, MediSapiens chief executive Kang Sang-gu, Lotte Biologics technology-development head Han Jae-jun, Kangstem Biotech business-development head Eo Hae-gwan, Curacle business-development director Kim Jung-han, Daewoong Pharmaceutical BS business-development center head Yoon Seok-hyun, and Ceragen chief business officer Park Young-seop. The seniority of the roster underscores that these firms treated the event as a venue for concrete negotiation, not just visibility.

Platforms on Display

Several participants arrived with specific technology stories. Ceragen presented its ORGANOSCREEN drug-evaluation platform, an organoid-based system the company positions as able to reproduce models of hard-to-treat diseases with high fidelity—a pitch aimed squarely at pharma partners seeking better preclinical prediction. Pangen highlighted a one-stop CDMO offering built on its patented production cell lines, targeting biologics developers that want manufacturing and cell-line engineering handled together. Kangstem Biotech, a stem-cell specialist, and Curacle rounded out a group whose common thread was platform-level capability rather than a single asset.

A Pipeline Spanning Oncology to Obesity

On the therapeutic side, Ildong Group used the meeting to lay out an R&D pipeline reaching across oncology, obesity, and rare disease—three of the most competitive and capital-intensive areas in global drug development. Presenting breadth of that kind at an international partnering forum is a signal of intent to license programs outward and to recruit co-development partners with deeper pockets and later-stage infrastructure.

Daewoong’s Long Runway

Among the delegation, Daewoong Pharmaceutical carries one of the longer corporate histories. The Seoul-based, publicly listed drugmaker—which produces both prescription and over-the-counter medicines—traces its lineage to Kawai Pharmaceutical Company, established in 1942. The business was formally incorporated as Daehan Vitamin Chemical in 1945, rebranded as Daehan Vitamin Industrial in 1961, and changed hands in 1966 when Yoon Young-hwan took over the then-struggling firm. It adopted its present name, Daewoong Pharmaceutical, in 1978. That eight-decade arc illustrates how some of the companies now courting overseas partners built their footing well before Korea became a recognized biotech exporter.

The Larger Picture

The recurring theme across the Korean presence was appetite for partnership: platform developers looking for pharma validation, a contract manufacturer offering integrated services, and a diversified group presenting a multi-indication pipeline. For an industry that has moved from generics and domestic sales toward licensing and global collaboration, a business-development-heavy showing at Bio USA is less a one-off and more a marker of where Korean pharma is heading.